0000950103-24-011230.txt : 20240730
0000950103-24-011230.hdr.sgml : 20240730
20240730210252
ACCESSION NUMBER: 0000950103-24-011230
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240726
FILED AS OF DATE: 20240730
DATE AS OF CHANGE: 20240730
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sukhatme Mayukh
CENTRAL INDEX KEY: 0001750050
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40782
FILM NUMBER: 241159591
MAIL ADDRESS:
STREET 1: C/O UOVANT SCIENCES, INC.
STREET 2: 5151 CALIFORNIA AVENUE, SUITE 250
CITY: IRVINE
STATE: CA
ZIP: 92617
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Roivant Sciences Ltd.
CENTRAL INDEX KEY: 0001635088
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 981173944
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: CLARENDON HOUSE, 2 CHURCH STREET
CITY: HAMILTON HM11
STATE: D0
ZIP: HM11
BUSINESS PHONE: 441-295-5950
MAIL ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
4
1
dp20157011_4-sukhatme.xml
FORM 4
X0508
4
2024-07-26
0
0001635088
Roivant Sciences Ltd.
ROIV
0001750050
Sukhatme Mayukh
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY
LONDON
X0
SW1H 0DB
UNITED KINGDOM
1
1
0
0
Pres&Chief Investment Officer
0
Common Shares
2024-07-26
4
A
0
1836547
0
A
5488532
D
Common Shares
2024-07-26
4
A
0
17000000
0
A
22488532
D
Common Shares
1657698
I
By LLC
Reflects an award of restricted stock units with respect to Common Shares ("RSUs"), with a vesting commencement date of March 31, 2025, which service-vest (i) 20% on the first anniversary of the vesting commencement date and (ii) in 16 successive equal quarterly installments thereafter, subject to the reporting person's continuous service through the applicable vesting date.
Reflects an award of performance restricted stock units with respect to Common Shares ("PSUs") across six share price hurdle tranches, as follows: $15.00 (14.71% of PSUs); $17.50 (7.35% of PSUs); $20.00 (8.82% of PSUs); $22.50 (11.77% of PSUs); $25.00 (22.06% of PSUs); and $30.00 (35.29% of PSUs). The PSUs will vest tranche-by-tranche on the first date that both the performance condition and the service condition with respect to the applicable tranche of the PSUs has been satisfied. The performance condition will be deemed satisfied for each tranche of PSUs on the first date, during the performance period ending on the five-year anniversary of the grant date, when the Company's trailing 30-day volume weighted average trading price per share exceeds the share price hurdle applicable to such tranche (as specified above).
The service condition will be deemed satisfied for each tranche of PSUs on the first anniversary of the date on which the performance condition is first satisfied with respect to such tranche, subject to the reporting person's continuous service through such anniversary. In addition, following the satisfaction of the performance condition and service condition and the vesting of any tranche of the PSUs, the common shares underlying the applicable vested tranche of PSUs are subject to a further two-year holding period before such common shares may be sold.
Reflects common shares held by a limited liability company (the "LLC") that is owned by a family trust (the "Trust"). The reporting person has investment control over both the LLC and the Trust. The reporting person disclaims beneficial ownership of the reported securities held by the LLC except to the extent of his pecuniary interest therein.
By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme
2024-07-30